Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292

Clinical and Experimental Metastasis

Volumn 28, Issue 7, 2011, Pages 649-659

  Furugaki, Koh ^a   Moriya, Yoichiro ^a   Iwai, Toshiki ^a   Yorozu, Keigo ^a   Yanagisawa, Mieko ^a   Kondoh, Kumiko ^a   Fujimoto Ohuchi, Kaori ^a   Mori, Kazushige ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Epidermal growth factor receptor; Osteoclast; Osteolytic bone invasion model; Tyrosine kinase inhibitor

Indexed keywords

ERLOTINIB; INTERLEUKIN 11; INTERLEUKIN 8; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RELATED PROTEIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL ACTIVATION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PROTEIN EXPRESSION; SCID MOUSE; STROMA CELL;

ANIMALS; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; NEOPLASM INVASIVENESS; OSTEOBLASTS; OSTEOLYSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 82355163597     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-011-9398-4     Document Type: Article

References (44)

1. RE Coleman 2001 Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 3 165 176 11417967 10.1053/ctrv.2000.0210 1:CAS:528:DC%2BD3MXktlCktb4%3D (Pubitemid 32452017)
2. VMD Hirsh PPMDF Major AMD Lipton, et al. 2008 Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity J Thorac Oncol 3 3 228 236 18317064 10.1097/JTO.0b013e3181651c0e (Pubitemid 351654321)
3. J Dancey EA Sausville 2003 Issues and progress with protein kinase inhibitors for cancer treatment Nat Rev Drug Discov 2 4 296 313 12669029 10.1038/nrd1066 1:CAS:528:DC%2BD3sXisFWkt70%3D (Pubitemid 37361688)
4. C-PMD Schneider DMD Heigener KMD Schott-von-Romer, et al. 2008 Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the TRUST study J Thorac Oncol 3 12 1446 1453 19057271 10.1097/JTO.0b013e31818ddcaa
5. M Pan M Santamaria DB Wollman 2007 CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation Nat Clin Pract Oncol 4 10 603 607 17898810 10.1038/ncponc0931 1:CAS:528:DC%2BD2sXhtV2isb7O (Pubitemid 47534759)
6. Y Okano M Nishio 2008 Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis Clin Calcium 18 4 527 533 18379035 1:CAS:528:DC%2BD1cXmvVOlu78%3D
7. H Sugiura K Yamada T Sugiura, et al. 2008 Predictors of survival in patients with bone metastasis of lung cancer Clin Orthop Relat Res 466 3 729 736 18196360 10.1007/s11999-007-0051-0
8. G Zampa M Moscato BW Brannigan, et al. 2008 Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib Lung Cancer 60 3 452 454 18079016 10.1016/j.lungcan.2007.11.002
9. H Satoh H Ishikawa G Ohara, et al. 2009 Prolonged response to gefitinib in bone metastasis Med Oncol 26 1 101 102 18607784 10.1007/s12032-008-9082-y
10. S-J Kim H Uehara T Karashima, et al. 2003 Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice Clin Cancer Res 9 3 1200 1210 12631626 1:CAS:528:DC%2BD3sXhvFKiur8%3D (Pubitemid 36323730)
11. KL Weber M Doucet JE Price, et al. 2003 Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice Cancer Res 63 11 2940 2947 12782601 1:CAS:528: DC%2BD3sXkt1ait7s%3D (Pubitemid 36667167)
12. A Angelucci GL Gravina N Rucci, et al. 2006 Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice Endocr Relat Cancer 13 1 197 210 16601288 10.1677/erc.1.01100 1:CAS:528:DC%2BD28XltlKku7o%3D
13. N Normanno A De Luca D Aldinucci, et al. 2005 Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis Endocr Relat Cancer 12 2 471 482 15947117 10.1677/erc.1.00956 1:CAS:528:DC%2BD2MXnsl2nu7w%3D (Pubitemid 40896460)
14. N Normanno WJ Gullick 2006 Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocr Relat Cancer 13 1 3 6 16601275 10.1677/erc.1.01185 1:CAS:528:DC%2BD28XltlKktLc%3D
15. BT Feeley NQ Liu AH Conduah, et al. 2006 Mixed metastatic lung cancer lesions in bone are inhibited by Noggin overexpression and rank: Fc administration J Bone Miner Res 21 10 1571 1580 16995812 10.1359/jbmr.060706 1:CAS:528:DC%2BD28XhtFekt7zO (Pubitemid 44484602)
16. A Sasaki K Kitamura RE Alcalde, et al. 1998 Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice Int J Cancer 77 2 279 285 9650565 10.1002/(SICI)1097-0215(19980717)77:2<279::AID- IJC18>3.0.CO;2-6 1:CAS:528:DyaK1cXkt1GgsLo%3D (Pubitemid 28287982)
17. N Amizuka J Shimomura M Li, et al. 2003 Defective bone remodelling in osteoprotegerin-deficient mice J Electron Microsc (Tokyo) 52 6 503 513 10.1093/jmicro/52.6.503 1:CAS:528:DC%2BD2cXptFCmtw%3D%3D (Pubitemid 38092538)
18. K Furugaki T Iwai K Kondoh, et al. 2010 Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers Oncol Lett 1 231 235 10.3892/ol-00000041 1:CAS:528: DC%2BC3cXktVWntbY%3D
19. JJ Yin CB Pollock K Kelly 2005 Mechanisms of cancer metastasis to the bone Cell Res 15 1 57 62 15686629 10.1038/sj.cr.7290266 1:CAS:528: DC%2BD2MXkslGisbc%3D (Pubitemid 41653967)
20. GD Roodman 2007 Bone-breaking cancer treatment Nat Med 13 1 25 26 17206127 10.1038/nm0107-25 1:CAS:528:DC%2BD2sXhvFSrug%3D%3D (Pubitemid 46067377)
21. TA Guise 2009 Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases Genes Dev 23 18 2117 2123 19759260 10.1101/gad.1854909 1:CAS:528:DC%2BD1MXht1ersbrJ
22. S Sakai H Takaishi K Matsuzaki, et al. 2009 1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression J Bone Miner Metab 27 6 643 652 19449179 10.1007/s00774-009-0084-4 1:CAS:528:DC%2BD1MXhtlKjt77O
23. N Udagawa N Takahashi E Jimi, et al. 1999 Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor Bone 25 5 517 523 10574571 10.1016/S8756-3282(99)00210-0 1:CAS:528:DyaK1MXmvVKju78%3D (Pubitemid 29469457)
24. K Wang H Yamamoto JR Chin, et al. 2004 Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment J Biol Chem 279 51 53848 53856 15456762 10.1074/jbc.M403114200 1:CAS:528:DC%2BD2cXhtVKqu7vO (Pubitemid 40051894)
25. LE Quint S Tummala LJ Brisson, et al. 1996 Distribution of distant metastases from newly diagnosed non-small cell lung cancer Ann Thorac Surg 62 1 246 250 8678651 10.1016/0003-4975(96)00220-2 1:STN:280:DyaK283ms1ansA%3D%3D (Pubitemid 26239872)
26. AF Chambers AC Groom IC MacDonald 2002 Metastasis: dissemination and growth of cancer cells in metastatic sites Nat Rev Cancer 2 8 563 572 12154349 10.1038/nrc865 1:CAS:528:DC%2BD38XlslGqsLw%3D (Pubitemid 37328923)
27. GR Mundy 2002 Metastasis: metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 8 584 593 12154351 10.1038/nrc867 1:CAS:528:DC%2BD38XlslGqsLo%3D (Pubitemid 37328925)
28. T Yoneda T Hiraga 2005 Crosstalk between cancer cells and bone microenvironment in bone metastasis Biochem Biophys Res Commun 328 3 679 687 15694401 10.1016/j.bbrc.2004.11.070 1:CAS:528:DC%2BD2MXhtVKhsbY%3D (Pubitemid 40208305)
29. G von Minckwitz W Jonat P Fasching, et al. 2005 A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer Breast Cancer Res Treat 89 2 165 172 10.1007/s10549-004-1720-2 1:CAS:528:DC%2BD2MXhtVamsro%3D (Pubitemid 40249050)
30. A Marchetti C Martella L Felicioni, et al. 2005 EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment J Clin Oncol 23 4 857 865 15681531 10.1200/JCO.2005.08.043 1:CAS:528:DC%2BD2MXitVKit7o%3D (Pubitemid 46224186)
31. YH Soung JW Lee SY Kim, et al. 2005 Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas Virchows Arch 446 5 483 488 15815931 10.1007/s00428-005-1254-y 1:CAS:528:DC%2BD2MXksl2gsro%3D (Pubitemid 40884280)
32. S Kitazawa R Kitazawa 2002 RANK ligand is a prerequisite for cancer-associated osteolytic lesions J Pathol 198 2 228 236 12237883 10.1002/path.1199 1:CAS:528:DC%2BD3sXivV2js74%3D (Pubitemid 35243881)
33. N Matsuura W Puzon-McLaughlin A Irie, et al. 1996 Induction of experimental bone metastasis in mice by transfection of integrin alpha 4 beta 1 into tumor cells Am J Pathol 148 1 55 61 8546226 1:CAS:528:DyaK28Xitlahs7Y%3D (Pubitemid 26019643)
34. Y Zhao R Bachelier I Treilleux, et al. 2007 Tumor αvβ3 integrin is a therapeutic target for breast cancer bone metastases Cancer Res 67 12 5821 5830 17575150 10.1158/0008-5472.CAN-06-4499 1:CAS:528: DC%2BD2sXmsFCqtr8%3D (Pubitemid 46985016)
35. B Higgins K Kolinsky M Smith, et al. 2004 Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models Anti-cancer Drugs 15 5 503 512 15166626 10.1097/01.cad.0000127664.66472.60 1:CAS:528:DC%2BD2cXktlajsrc%3D (Pubitemid 38736950)
36. NJ Bundred WA Ratcliffe RA Walker, et al. 1991 Parathyroid hormone related protein and hypercalcaemia in breast cancer BMJ 303 6816 1506 1509 1782489 10.1136/bmj.303.6816.1506 1:STN:280:DyaK387ksFWitA%3D%3D
37. CC Bancroft Z Chen G Dong, et al. 2001 Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-κB signal pathways Clin Cancer Res 7 2 435 442 11234901 1:CAS:528:DC%2BD3MXhvFKntrs%3D (Pubitemid 32183050)
38. S Bamba A Andoh H Yasui, et al. 2003 Regulation of IL-11 expression in intestinal myofibroblasts: role of c-Jun AP-1- and MAPK-dependent pathways Am J Physiol Gastrointest Liver Physiol 285 3 G529 G538 12760902 1:CAS:528: DC%2BD3sXnsVGmur4%3D (Pubitemid 37021812)
39. G Lorch JL Gilmore PF Koltz, et al. 2007 Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice Br J Cancer 97 2 183 193 17533397 10.1038/sj.bjc.6603828 1:CAS:528:DC%2BD2sXnsFaqsLo%3D (Pubitemid 47057466)
40. T Yi H-L Lee J-H Cha, et al. 2008 Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling J Cell Physiol 217 2 409 422 18543257 10.1002/jcp.21511 1:CAS:528:DC%2BD1cXht1eltrbF
41. M Krampera A Pasini A Rigo, et al. 2005 HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation Blood 106 1 59 66 15755902 10.1182/blood-2004-09- 3645 1:CAS:528:DC%2BD2MXlvVWjs7s%3D (Pubitemid 40967175)
42. MR Schneider M Sibilia RG Erben 2009 The EGFR network in bone biology and pathology Trends Endocrinol Metab 20 10 517 524 19819718 10.1016/j.tem.2009.06. 008 1:CAS:528:DC%2BD1MXhsVGrur3E
43. K Tamama H Kawasaki A Wells 2010 Epidermal growth factor (EGF) treatment on multipotential stromal cells (MSCs). Possible enhancement of therapeutic potential of MSC J Biomed Biotechnol 2010 795385 20182548 10.1155/2010/795385
44. DL Lacey E Timms HL Tan, et al. 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 2 165 176 9568710 10.1016/S0092-8674(00)81569-X 1:CAS:528:DyaK1cXivVyhtrg%3D (Pubitemid 28180851)